BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Sep 22, 2008
 |  BC Week In Review  |  Clinical News  |  Regulatory

Aztreonam lysine regulatory update

Gilead received a complete response letter from FDA for an NDA for an inhaled formulation of Aztreonam lysine to treat cystic fibrosis (CF) patients who have Pseudomonas...

Read the full 113 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >